These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36349202)

  • 1. Erratum: Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma.
    Clin Transl Immunology; 2022; 11(11):e1429. PubMed ID: 36349202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma.
    Alvarez-Fernández C; Escribà-Garcia L; Caballero AC; Escudero-López E; Ujaldón-Miró C; Montserrat-Torres R; Pujol-Fernández P; Sierra J; Briones J
    Clin Transl Immunology; 2021; 10(4):e1268. PubMed ID: 33968404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum: Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma.
    Abbott RC; Verdon DJ; Gracey FM; Hughes-Parry HE; Iliopoulos M; Watson KA; Mulazzani M; Luong K; D'Arcy C; Sullivan LC; Kiefel BR; Cross RS; Jenkins MR
    Clin Transl Immunology; 2021; 10(7):e1317. PubMed ID: 34295472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum: Clinical chimeric antigen receptor T-cell therapy: a new and promising treatment modality for glioblastoma.
    Brown MP; Ebert LM; Gargett T
    Clin Transl Immunology; 2021; 10(8):e1331. PubMed ID: 34401149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
    Ramos CA; Ballard B; Zhang H; Dakhova O; Gee AP; Mei Z; Bilgi M; Wu MF; Liu H; Grilley B; Bollard CM; Chang BH; Rooney CM; Brenner MK; Heslop HE; Dotti G; Savoldo B
    J Clin Invest; 2017 Sep; 127(9):3462-3471. PubMed ID: 28805662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges of driving CD30-directed CAR-T cells to the clinic.
    Grover NS; Savoldo B
    BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
    Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
    Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30.
    Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
    Cancer Res; 1998 Mar; 58(6):1116-9. PubMed ID: 9515791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
    Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
    Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
    Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30
    Zhang P; Yang X; Cao Y; Wang J; Zhou M; Chen L; Wei J; Mao Z; Wang D; Xiao Y; Zhu H; Zhang S; Zhang T; Zhang Y; Zhou J; Huang L
    Exp Hematol Oncol; 2022 Oct; 11(1):72. PubMed ID: 36253833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.
    Eberle FC; Song JY; Xi L; Raffeld M; Harris NL; Wilson WH; Pittaluga S; Jaffe ES
    Am J Surg Pathol; 2012 May; 36(5):716-25. PubMed ID: 22367293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum: Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
    Bai Y; Kan S; Zhou S; Wang Y; Xu J; Cooke JP; Wen J; Deng H
    Cell Discov; 2016; 2():16032. PubMed ID: 27625791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum: Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
    Bai Y; Kan S; Zhou S; Wang Y; Xu J; Cooke JP; Wen J; Deng H
    Cell Discov; 2016; 2():15052. PubMed ID: 27462841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.
    Hombach AA; Görgens A; Chmielewski M; Murke F; Kimpel J; Giebel B; Abken H
    Mol Ther; 2016 Aug; 24(8):1423-34. PubMed ID: 27112062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.
    Zhang S; Gu C; Huang L; Wu H; Shi J; Zhang Z; Zhou Y; Zhou J; Gao Y; Liu J; Leng Y; Liu X; Zhang Q; Huang L; Tong X; Young KH; Li J; Zhu H; Zhang T
    Sci Rep; 2022 Jun; 12(1):10488. PubMed ID: 35729339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
    Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
    Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
    Di Stasi A; De Angelis B; Rooney CM; Zhang L; Mahendravada A; Foster AE; Heslop HE; Brenner MK; Dotti G; Savoldo B
    Blood; 2009 Jun; 113(25):6392-402. PubMed ID: 19377047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
    Hunter BD; Chen YB; Jacobson CA
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.